Nippon Life Global Investors Americas Inc. Raises Stock Position in Eli Lilly and Company $LLY

Key Points

• Nippon Life Global Investors Americas Inc. increased its stake in Eli Lilly and Company by 8.0%, holding 69,790 shares valued at approximately $57.64 million.
• Eli Lilly recently reported $6.31 EPS for the quarter, beating estimates by $0.72 and showing a 37.6% year-over-year revenue growth.
• The company declared a quarterly dividend of $1.50 per share, reflecting an annualized payout of $6.00 and a dividend yield of 0.8%.

Nippon Life Global Investors Americas Inc. raised its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 8.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 69,790 shares of the company's stock after buying an additional 5,180 shares during the period. Eli Lilly and Company accounts for about 2.8% of Nippon Life Global Investors Americas Inc.'s portfolio, making the stock its 10th largest holding. Nippon Life Global Investors Americas Inc.'s holdings in Eli Lilly and Company were worth $57,640,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. increased its stake in shares of Eli Lilly and Company by 97.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company's stock worth $83,669,349,000 after purchasing an additional 50,002,551 shares during the last quarter. GAMMA Investing LLC boosted its holdings in shares of Eli Lilly and Company by 103,831.6% during the 1st quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company's stock worth $12,278,292,000 after buying an additional 14,852,076 shares during the period. Nuveen LLC bought a new stake in shares of Eli Lilly and Company during the 1st quarter worth about $4,613,912,000. Vanguard Group Inc. boosted its holdings in shares of Eli Lilly and Company by 6.7% during the 1st quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company's stock worth $65,432,218,000 after buying an additional 4,975,395 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Eli Lilly and Company by 15.9% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,084,880 shares of the company's stock worth $5,469,527,000 after buying an additional 969,376 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, Director Jamere Jackson purchased 200 shares of the company's stock in a transaction dated Friday, August 8th. The stock was purchased at an average price of $639.56 per share, with a total value of $127,912.00. Following the completion of the purchase, the director owned 9,402 shares of the company's stock, valued at approximately $6,013,143.12. The trade was a 2.17% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Daniel Skovronsky purchased 1,000 shares of the company's stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average cost of $634.40 per share, with a total value of $634,400.00. Following the purchase, the executive vice president directly owned 137,660 shares of the company's stock, valued at approximately $87,331,504. The trade was a 0.73% increase in their position. The disclosure for this purchase can be found here. Insiders acquired 4,514 shares of company stock worth $2,894,841 over the last 90 days. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock traded down $16.56 during midday trading on Friday, hitting $726.35. The company's stock had a trading volume of 3,953,474 shares, compared to its average volume of 5,282,453. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $942.35. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The company has a 50-day moving average price of $743.84 and a two-hundred day moving average price of $781.22. The company has a market cap of $687.46 billion, a price-to-earnings ratio of 47.47, a PEG ratio of 1.01 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business's revenue for the quarter was up 37.6% compared to the same quarter last year. During the same period in the previous year, the company earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, sell-side analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be given a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date is Friday, August 15th. Eli Lilly and Company's dividend payout ratio is currently 39.22%.

Analysts Set New Price Targets

LLY has been the subject of several research analyst reports. Guggenheim reduced their target price on shares of Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating for the company in a report on Wednesday, August 13th. HSBC raised shares of Eli Lilly and Company from a "reduce" rating to a "hold" rating and lifted their target price for the stock from $675.00 to $700.00 in a report on Wednesday, August 27th. Cantor Fitzgerald reduced their target price on shares of Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating for the company in a report on Wednesday, August 13th. UBS Group reduced their target price on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating for the company in a report on Friday, August 8th. Finally, Deutsche Bank Aktiengesellschaft reduced their target price on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating for the company in a report on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and eight have assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $950.17.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.